Io Biotech Inc (IOBT) Stock Price, Quote & News

Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 29 80

Website: www.iobiotech.com

Address:

Ole MaalOees Vej 3, Copenhagen N, Copenhagen, Denmark

therealcryptocowboy Feb. 4 at 12:06 AM

$IOBT when announcement🤔👀😤

1 · Reply

badprecog Feb. 4 at 12:05 AM

$IOBT I think anything under probably .40 per share a deal is not doable as shareholders will just be like no liquidate it. So I think anything under that is a blind man’s bluff. Drug is worth $500 million min as it sites. Way more if anyone at big pharma has a brain.

1 · Reply

VinnyLaw Feb. 3 at 10:56 PM

$IOBT Adding more here. I expect a favorable sale of the company in excess of $.5 per share.

0 · Reply

justiceforb_85 Feb. 3 at 8:20 PM

$IOBT adding on a hail mary for the company..

0 · Reply

LordWorld Feb. 3 at 4:50 PM

$IOBT I've seen a lot, and I'm always ready for it.🤣

0 · Reply

therealcryptocowboy Feb. 3 at 4:37 PM

$IOBT shorts could get torched here, hoping for ah news. Not seeing it happening before that!

0 · Reply

therealcryptocowboy Feb. 3 at 1:43 PM

$IOBT added more here😤🤷🏻‍♂️🤔

0 · Reply

LordWorld Feb. 3 at 11:45 AM

$IOBT Zacks 🟢BUY - 🎯 -1,62 $ . forecast from January 31, 2026

0 · Reply

Nvidioso Feb. 3 at 11:37 AM

$IOBT Today can be a very good day!! Waiting for the announcement...

0 · Reply

justiceforb_85 Feb. 3 at 2:37 AM

$IOBT wondering if there is any hope for this? Science is good but the trial was under-powered. $MRNA with a similar molecule but not in P3.

0 · Reply

IO Biotech Provides Corporate Update

Jan 21, 2026, 5:30 AM EST - 13 days ago

IO Biotech Announces Exploration of Strategic Alternatives

Dec 15, 2025, 4:05 PM EST - 7 weeks ago

IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications

Nov 26, 2025, 10:46 AM EST - 2 months ago

IO Biotech Announces Participation in Upcoming December Investor Conferences

Nov 14, 2025, 8:05 AM EST - 2 months ago

IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Nov 12, 2025, 8:30 AM EST - 2 months ago

IO Biotech Announces Participation in Upcoming Investor Conferences

Nov 7, 2025, 9:00 AM EST - 3 months ago

IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 20, 2025, 2:30 AM EDT - 3 months ago

IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Sep 29, 2025, 7:05 AM EDT - 4 months ago

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

Sep 23, 2025, 8:05 AM EDT - 4 months ago

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

Sep 9, 2025, 11:41 AM EDT - 5 months ago

IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 14, 2025, 4:05 PM EDT - 6 months ago

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 12, 2025, 4:17 PM EDT - 6 months ago

IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma

Aug 11, 2025, 8:24 AM EDT - 6 months ago

IO Biotech's cancer vaccine shows improvement in late-stage study goal

Aug 11, 2025, 8:00 AM EDT - 6 months ago

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Aug 10, 2025, 8:00 AM EDT - 6 months ago

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

May 20, 2025, 8:05 AM EDT - 9 months ago

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

May 14, 2025, 8:05 AM EDT - 9 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Apr 26, 2025, 3:05 PM EDT - 10 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 10 months ago

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

Mar 25, 2025, 4:35 PM EDT - 11 months ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 18, 2025, 8:00 AM EDT - 11 months ago

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Mar 4, 2025, 4:17 PM EST - 1 year ago

IO Biotech Reports 2024 Business Highlights

Feb 23, 2025, 12:07 PM EST - 1 year ago

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Feb 20, 2025, 8:05 AM EST - 1 year ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Feb 4, 2025, 8:05 AM EST - 1 year ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Jan 9, 2025, 8:05 AM EST - 1 year ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Dec 20, 2024, 8:05 AM EST - 1 year ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Nov 12, 2024, 7:05 AM EST - 1 year ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 7, 2024, 10:00 AM EST - 1 year ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Oct 4, 2024, 9:00 AM EDT - 1 year ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 14, 2024, 2:30 AM EDT - 1 year ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Aug 30, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 13, 2024, 7:05 AM EDT - 1 year ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 25, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

May 23, 2024, 8:30 AM EDT - 1 year ago

IO Biotech to Present at Jefferies Global Healthcare Conference

May 14, 2024, 7:55 AM EDT - 1 year ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 24, 2024, 4:30 PM EDT - 1 year ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Apr 5, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Mar 6, 2024, 4:11 PM EST - 2 years ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:40 PM EST - 2 years ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Feb 26, 2024, 4:05 PM EST - 2 years ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Jan 3, 2024, 3:04 AM EST - 2 years ago

IO Biotech: A Phase 3 Company Getting No Respect

Dec 21, 2023, 8:30 AM EST - 2 years ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Nov 13, 2023, 8:12 AM EST - 2 years ago

IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:00 AM EST - 2 years ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Nov 10, 2023, 8:00 AM EST - 2 years ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Nov 1, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

therealcryptocowboy Feb. 4 at 12:06 AM

$IOBT when announcement🤔👀😤

1 · Reply

badprecog Feb. 4 at 12:05 AM

1 · Reply

VinnyLaw Feb. 3 at 10:56 PM

$IOBT Adding more here. I expect a favorable sale of the company in excess of $.5 per share.

0 · Reply

justiceforb_85 Feb. 3 at 8:20 PM

$IOBT adding on a hail mary for the company..

0 · Reply

LordWorld Feb. 3 at 4:50 PM

$IOBT I've seen a lot, and I'm always ready for it.🤣

0 · Reply

therealcryptocowboy Feb. 3 at 4:37 PM

$IOBT shorts could get torched here, hoping for ah news. Not seeing it happening before that!

0 · Reply

therealcryptocowboy Feb. 3 at 1:43 PM

$IOBT added more here😤🤷🏻‍♂️🤔

0 · Reply

LordWorld Feb. 3 at 11:45 AM

$IOBT Zacks 🟢BUY - 🎯 -1,62 $ . forecast from January 31, 2026

0 · Reply

Nvidioso Feb. 3 at 11:37 AM

$IOBT Today can be a very good day!! Waiting for the announcement...

0 · Reply

justiceforb_85 Feb. 3 at 2:37 AM

$IOBT wondering if there is any hope for this? Science is good but the trial was under-powered. $MRNA with a similar molecule but not in P3.

0 · Reply

LordWorld Feb. 2 at 7:53 PM

$IOBT Let's have some fun

0 · Reply

LordWorld Feb. 2 at 5:01 PM

$IOBT IOBT 🟢Closed negotiations! Biopharma Mogul Summit Organized by: Piper Sandler Investment Bank Where: Park City, Utah (USA) When: February 1–3, 2026 (including today, February 2) Purpose: This is a closed investment event for senior executives of biopharmaceutical and biotechnology companies, investors, and analysts. The goal is informal, private meetings (one-on-one) to discuss investments, partnerships, and potential M&A transactions. ⚠️Now it's clear why they issued two press releases on January 30th, rushed to sign a contract with Raymond James, and announced the dismissal of top manager Kassim Ahmad and the layoff of all staff. The team that worked on T-Win remained and continues to work. In other words, they "cleaned" the company of unnecessary ballast and are ready for sale.

4 · Reply

Sanaci Feb. 2 at 12:38 PM

Nothing substantial: $OSTX keeps going down the $IOBT way

1 · Reply

LordWorld Feb. 2 at 6:11 AM

$IOBT The remaining employees and subordinates are unnecessary waste. That's why, on January 30, 2026, IOBT's press release, following the announcement of Raymond James' hiring, issued a separate statement about Kassim Ahmed's layoffs, with compensation payments. Raymond James is cleaning up and "packaging IOBT" for sale. It seems to me that there's already a buyer, and not just one. One who has set the conditions for IOBT to get rid of all unnecessary stuff. Kassim Ahmed also owns IOBT shares; he bought them with his own money (not a bonus from IOBT), and he hasn't sold a single one yet!

1 · Reply

LordWorld Feb. 1 at 9:08 AM

$IOBT Have you ever wondered why they didn't fire everyone? 🤣 The answer is, whoever acquires it needs the team that worked on T win!!!

1 · Reply

badprecog Jan. 30 at 8:19 PM

$IOBT The more I think about it, the more I think Regeneron could be a buyer. They have a dual action checkpoint inhibitor, but if you had IO Biotech's drug and run it as a 4-pronged therapy. You know you are going to blow out in pdl1- which will be 30-40% of the trial. This drug really is a trail insurance policy for someone. Avg Oncology Drug is $2.6 billion with all the failures to get to approval. One that could put your checkpoint inhibitor in a dominant position... If Raymond James can do a good job here things could end up between crappy and ok for investors. ;)

1 · Reply

LordWorld Jan. 30 at 8:05 PM

$IOBT Scary? 🤣 I averaged it out. I bought shares at 0.298. The news about Raymond James is mostly positive because if such a giant took it on, it means 80% of the company will be sold and most likely there's already a buyer. The fact that it fell is due to external sentiment; the entire market is sliding today, and it's Friday. If things were that bad, why wasn't the price 0.05-0.1???Good luck

0 · Reply

badprecog Jan. 30 at 3:57 PM

$IOBT Right now the pitch RJ is giving: "You have a checkpoint inhibitor, I have a drug that will likely give you the pdl1- market in multiple markets. Low toxicity, if you don't want it, that's ok but don't be mad at me when you lose half the market."

0 · Reply

LordWorld Jan. 30 at 3:25 PM

$IOBT Raymond James is a top-tier player in the healthcare sector. They don't take on hopeless cases unless they have something to sell. The fact that they signed on to the deal confirms that the T-win platform has market value and can be sold.

0 · Reply

badprecog Jan. 30 at 2:25 PM

$IOBT Raymond James specializes in selling 100 million to 2 billion dollar distressed bio assets. So it is the right firm for us. Hopefully they get it done.

1 · Reply

LordWorld Jan. 30 at 8:14 AM

$IOBT Piper Sandler previously released a release on January 26, 2026, where he emphasized that T-Win was a viable product. However, due to financial problems, he lowered the price to $0.50 and gave it a "Neutral" rating—not "Sell," but "Neutral." A $0.50 price tag is a valuation of T-Win's product; it can't be priced lower. And that's $35 million!??!!!? This is a ridiculous price for someone who'll buy it! Companies in Phase 2 are valued in the billions! And IOBT has a ready-made Phase 3 product, and it's universal! (Bureaucratic pressure and a lack of funds led to this situation).

0 · Reply

LordWorld Jan. 30 at 8:05 AM

$IOBT Currently, a "quiet period" is being observed by IOBT management and insiders to avoid future accusations of stock manipulation. I am confident that management is actively engaged in dialogue with everyone interested in the product, and there are many. The main issue is the evaluation of the entire company, as well as the team that has been working on T-Win for decades.

0 · Reply

Market Cap	20.87M
Revenue (ttm)	0.00
Net Income (ttm)	-95.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	18.31

Volume	1,919,100
Avg Vol	11,443,233
Day's Range	N/A - N/A
Shares Out	71.95M
Stochastic %K	13%
Beta	0.48
Analysts	Sell
Price Target	$1.62